The human iPSC cell line, CARS-FiPS4F1 (ESi064-A), derived from dermal ibroblast from the apparently healthy carrier of the mutation of the gene SACSIN, was generated by non-integrative reprogramming technology using OCT3/4, SOX2, CMYC and KLF4 reprogramming factors. The pluripotency was assessed by immunocytochemistry and RT-PCR. This iPSC line can be used as control for Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) disease.
Resource utility
Human induced pluripotent stem cells (hiPSC) from the healthy unafected carrier could serve as control for hiPSC derived from ARSACs patient. These cells can be diferentiated toward afected cells to better understand molecular mechanisms of disease and pathophysiology.
Resource details
Skin punch biopsy was taken from a 29-year-old healthy female individual which SACS gene was sequenced due to family relationship to persons that have been diagnosed for autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) harboring the c.11374C > T (p.R3792X) mutation in heterozygosis. Primary ibroblast cell line was established. The generation of the human induced pluripotent stem cell (hiPSC) line, CARS-FiPS4F1 (registered as ESi064-A at www.hPSCreg. com), was carried out using non-integrative Sendai virus containing the human reprogramming factors, Oct3/4, Sox2, C-Myc, Klf4 (Takahashi et al., 2007) following instructions by manufacturer. After 30 days generated colonies displayed a typical ES-like morphology (polygonal shape; refractive edges, high nuclear/cytoplasmic ratio) and growth behaviour. DNA sequencing analysis of CARS-FiPS4F1 conirmed the mutation in one allele in SACS (Fig. 1A) . The clearance of the virus and the exogenous reprogramming factor genes was conirmed by RT-PCR after twelve cell culture passages (Fig. 1B) . The genetic ingerprinting was performed with CARS-FiPS4F1 hiPSC line and proved its genetic identity to parental ibroblasts (available with the author). The selected line karyotypicaly showed normal karyotype (46, XY) at low passages (passage9) (Fig. 1C ) and medium passage number (passage 30). Genetic and functional assays were performed to determine the quality of the CARS-FiPS4F1 line. Pluripotency was assessed by immunocytochemistry to pluripotency markers OCT-4, SOX2, NANOG and SSEA-4 and low cytometry for SSEA-4 pluripotency marker (Fig. 1D ). The alkaline phosphatase is known to be more active in hiPSCs and the colorimetric assay depicting its activity conirmed that the selected hiPSC colonies are indeed pluripotent (Fig. 1D) . The expression of endogenous plutipotency genes was detected by RT-PCR (Fig. 1E) . To test the ability of the hiPSC line to generate derivates of three germ layers in vitro, the hiPSC were diferentiated into the three germ layers using an embryoid body based assay. Spontaneous diferentiated cells were immunostained for diferentiation markers such as TUJ1 for ectoderm, SMA for mesoderm and positive FOXA2 and Alfa-Feto protein (aFP) for endoderm (Fig. 1F) . The mycoplasma was regularly checked without positive results ( Supplementary Fig. 1 ).
Materials and methods

Reprogramming patient's fibroblasts
The hiPSC were derived from patient's ibroblasts using Sendai virus (Cyto Tune-iPS 2.0 reprogramming Kit, Life Technologies) according to manufacturer instructions. hiPSCs were grown on irradiated (45Gy) human foreskin ibroblasts (ATCC CRL 2429) in hiPSCs medium containing KO DMEM, KSR 20%, Glutamax 2 mM, non-essential amino acids 0.1 mM, β-mercaptoethanol 0.23 mM, basic FGF 10 ng/mL, penicillin/streptomycin. Cells were mechanically passaged every 6-8 days.
In vitro differentiation assay
For in vitro diferentiation assay the colonies from a fully conluent 6-well plate were cut mechanically and cultured in suspension to form embryoid bodies in hiPSCs media without bGFG. After 7 days in suspension, embryoid bodies were transferred into 0.1% gelatin-coated plates and cultured in same medium for additional 7-10 days to allow spontaneous diferentiation. Then the cells were ixed and immunostained to detect cells from the three germ layers.
Karyotype analysis
The hiPSCs were adapted to feeder-free cell culture on Matrigel (BD, #354277) coated plates using mTeSR1 medium. Passages were performed using Dispase (STEMCELL Technologies, #07913), every 5-7 days. The karyotype was analyzed by G-banding at 400-550 band resolution, 30 metaphases analyzed (Service of Biobanco de Sistema Sanitario Público, Granada, Spain).
Fingerprinting
gDNA from ibroblasts and hiPSCs was extracted using QIAamp DNA Blood mini kit (Qiagen, Hilden, Germany) in the presence of RNAse (Roche). Fingerprinting analyses was performed using 5 microsatellite markers (D19S572, D2S159, D14S972, D8S601and D9S1853) and analyzed on an Abi PRISM 3130 Genetic Analyzer using GeneMapper (Thermo Fisher) by Biobanco de Sistema Sanitario Público, Granada, Spain.
Mutation sequencing
Genomic DNA from ibroblasts and hiPSCs was isolated using the QIAamp DNA Blood mini kit (Qiagen). Primers used for ampliication and directed sequencing of SACS around the mutation site c.9938delC Sense: 5′-GCAGAACATCTCCTTCAGGA -3′, Antisense: 5′-CCGCTATG TAAGCATTGGAAA-3′ (Table 1) .
Detection of pluripotency markers by RT-PCR
Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany), and treated with DNase I to remove any genomic DNA contamination. QuantiTect Reverse Transcription Kit (Qiagen) was used to carry out cDNA synthesis from 1 μg of total RNA according to the manufacturer's instructions. The PCR reaction was performed with MyTaq DNA Polymerase (Bioline GmbH, Germany) using Applied Biosystems Veriti Thermal Cycler. The expression level of pluripotency markers was analyzed using the primers described in Table 2 . Fibroblasts and hESC H9 (WiCell) were used as negative and positive control respectively.
Immunocytochemistry
Cells were washed in PBS and ixed in 4% PFA for 15 min at room temperature (RT). Fixed cells were washed twice in PBS and placed in blocking solution (3% serum, 0.5% Triton-X100 in PBS) for 1 h at RT. Cells were then incubated overnight at 4°C with primary antibodies. The following day, cells were washed three times in PBS and incubated with an appropriate secondary antibody at RT for 1 h. Thereafter, cells were stained with DAPI (1:1000) at RT during 5 min, washed three times in PBS and visualized on Leica DM600 luorescent microscope equipped with Leica DC500 camera. Samples grown on coverslips were mounted using Vectashield.
Flow cytometry
hiPSCs were dissociated using Accutase (Innovative Cell Technologies) for 2-4 min at RT, centrifuged at 300 rcf for 5 min and resuspended in PBS + 2% FBS. Anti-human SSEA-4 antibody was added and incubated for 20 min at RT. IgG3, kappa isotype (STEMCELL technologies # 60073PE.1) was used as negative control. The cells were Table 2 Reagents details.
analyzed using a CytoFLEX low cytometer (Beckman Coulter) and data analyzed by CytExpert 2.0 software.
Alkaline phosphatase staining
Alkaline phosphatase staining was carried out using Alkaline Phosphatase Staining Kit II (Stemgent, MA).
Mycoplasma detection
The presence of mycoplasma was tested regularly measuring enzyme activity via luciferase (MycoAlert™ PLUS Mycoplasma Detection Kit, Lonza).
hiPSC Nomenclature
The generated hiPSC line was named following Spanish National Stem Cell Bank recommendations. The line is registered on https:// hpscreg.eu/ as ESi043-A line. 
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